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ABSTRACT
Introduction: Cognitive impairment is common
following stroke and can increase disability and levels
of dependency of patients, potentially leading to greater
burden on carers and the healthcare system. Effective
cardiovascular risk factor control through secondary
preventive medications may reduce the risk of cognitive
decline. However, adherence to medications is often
poor and can be adversely affected by cognitive
deficits. Suboptimal medication adherence negatively
impacts secondary prevention targets, increasing the
risk of recurrent stroke and further cognitive decline.
The aim of this study is to profile cognitive function
and secondary prevention, including adherence to
secondary preventive medications and healthcare
usage, 5 years post-stroke. The prospective
associations between cognition, cardiovascular risk
factors, adherence to secondary preventive
medications, and rates of recurrent stroke or other
cardiovascular events will also be explored.
Methods and analysis: This is a 5-year follow-up of
a prospective study of the Action on Secondary
Prevention Interventions and Rehabilitation in Stroke
(ASPIRE-S) cohort of patients with stroke. This cohort
will have a detailed assessment of cognitive function,
adherence to secondary preventive medications and
cardiovascular risk factor control.
Ethics and dissemination: Ethical approval for this
study was granted by the Research Ethics Committees
at Beaumont Hospital, Dublin and Connolly Hospital,
Dublin, Mater Misericordiae University Hospital, Dublin,
and the Royal College of Surgeons in Ireland. Findings
will be disseminated through presentations and peer-
reviewed publications.
INTRODUCTION
Stroke is one of the leading causes of death
and disability worldwide,1 with over half of
patients exhibiting signs of cognitive impair-
ment 6 months post-stroke.2 Deﬁcits in cogni-
tive function are associated with poor
functional outcomes, increased vulnerability
and poorer quality of life, and can increase
disability and levels of dependency, poten-
tially leading to a greater burden on carers
and the healthcare system.3 4 While there is
evidence to support early rehabilitation inter-
ventions post-stroke, less is known about the
reduction of longer term stroke-related dis-
ability.5 The chronic phase of stroke accounts
for a considerable proportion of the total
costs of stroke care, with measures to
improve long-term outcomes potentially
having a substantial impact on the economic
burden of stroke.6
Cardiovascular risk factor management and
secondary prevention
Several risk factors, including hypertension,
dyslipidaemia, diabetes, obesity and smoking,
are associated with both cardiovascular
disease and cognitive impairment. A study of
355 patients with stroke aged over 75 years
reported that the presence of three or more
cardiovascular risk factors increased the risk
of dementia during a mean follow-up of
3.8 years.7 Secondary preventive treatment,
including antihypertensive and anticoagulant
medications, has been associated with a
reduced risk of cognitive impairment
6 months post-stroke.2 Similarly, the use of
anticoagulant, antiplatelet and antihyperten-
sive medications was associated with a
reduced risk of cognitive impairment up to
7 years post-stroke in a sample of patients
with stroke from the South London Stroke
Register.8 Targeting cardiovascular risk
factors may reduce both the risk of recurrent
vascular events and the risk of cognitive
decline.2 7 9 Secondary prevention and
rehabilitation are thus essential to maximis-
ing health and well-being post-stroke, particu-
larly as recurrent strokes account for up to
50% of all strokes, indicating unsuccessful
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secondary prevention.10 However, there are limited
longer term follow-up data on patients with stroke, and a
lack of information regarding the adequacy of longer
term post-stroke secondary prevention.11 12 The Action
on Secondary Prevention Interventions and
Rehabilitation in Stroke (ASPIRE-S) study found a high
prevalence of cognitive impairment and cardiovascular
risk factors at 6 months post-stroke.2 4 11 While three-
quarters of the sample were on antihypertensive therapy,
almost two-thirds had blood pressure above the recom-
mended target of 140/90 mm Hg. Similarly, while 95%
of patients were on lipid-lowering medications, only
approximately three-quarters had total cholesterol or
low-density lipoprotein (LDL) cholesterol at European
guideline targets.11
Medication adherence
Effective secondary stroke prevention is contingent on
consistent adherence to prescribed secondary preventive
medications.13 Non-adherence is associated with adverse
outcomes, including rehospitalisation, recurring vascular
events and death, as well as increased costs of care.14 15
However, medication adherence is often poor, with up
to 50% of patients discontinuing secondary preventive
medications 2 years post-stroke.16 A recent systematic
review reported an estimated rate of non-adherence to
secondary preventive medications among stroke survi-
vors of 30.9% (95% CI 26.8% to 35.3%).17 A number of
factors were found to be related to non-adherence in
individual studies, including disability, reduced cognitive
function, polypharmacy and concerns about treat-
ment.17 However, this review also noted substantial het-
erogeneity in the inclusion criteria and deﬁnitions and
measurements of adherence, with several studies exclud-
ing patients with stroke with evidence of cognitive
impairment.
Medication adherence and cognitive function
Adherence to medication regimens requires a number
of cognitive skills that are affected by cognitive impair-
ment, including instructions for medication taking and
accessing and scheduling medications.18 Suboptimal
adherence, in turn, adversely impacts secondary preven-
tion targets, increasing the risk of recurrent stroke and
further cognitive decline.2 However, there is a scarcity of
data on longer term treatment continuation and adher-
ence rates in patients with stroke, with several studies of
adherence either not including cognitive assessments, or
focusing exclusively on adherence to antithrombotic
medications by patients with stroke and atrial ﬁbrilla-
tion.11 13 19–22 Further, previous studies of stroke out-
comes are limited by relatively short follow-ups and small
sample sizes, and may not reﬂect contemporary out-
comes or treatments.23
Thus, while secondary prevention may be related to a
reduced risk of cognitive impairment in patients with
stroke, few studies have examined the association
between adherence to secondary preventive medications
and cognitive impairment, and it is unclear whether sub-
optimal adherence affects the risk of later cognitive
impairment. Further, there are little data available at
present regarding the use of healthcare resources, out-
comes and costs post-stroke, or how these may be
impacted by cognitive impairment or inadequate secon-
dary prevention.24 The identiﬁcation of medication
adherence patterns, factors associated with adherence,
and the impact on clinical and cognitive outcomes can
inform the development of policies and interventions
focused on improving medication management.25 Given
the growing health, social and economic burden of cog-
nitive impairment and dementia, longer term follow-up
studies are needed to test these associations over
extended periods of time.3 20
Aims and objectives
The aim of this study is to proﬁle cognitive function and
secondary prevention, including healthcare usage and
adherence to secondary preventive medications, at
5 years post-stroke. Speciﬁcally, the objectives are:
▸ To provide a detailed description of cognitive func-
tion and secondary prevention, including medication
adherence at 5 years post-stroke;
▸ To investigate risk factor management, including
blood pressure and cholesterol control 5 years post-
stroke;
▸ To ascertain rates of recurrent stroke, other cardiovas-
cular events and death in the 5 years post-stroke;
▸ To explore the prospective associations between cog-
nition, cardiovascular risk factors and adherence to
secondary preventive medications from 6 months to
5 years post-stroke;
▸ To explore levels of agreement between self-reported
medication adherence assessed using a validated
scale, pill counts and adherence estimates using phar-
macy prescription reﬁll data, in this cohort of patients
with stroke;
▸ To explore longer term stroke rehabilitation and
healthcare usage, and their associations with cogni-
tion and secondary prevention 5 years post-stroke;
▸ To examine the longer term costs of stroke, in terms
of healthcare usage and quality of life, and their asso-
ciation with cognition and secondary prevention
5 years post-stroke.
A secondary aim is to explore carer well-being and the
reciprocal associations between changes in cognitive
function of patients with stroke and emotional distress
and vulnerability in carers or family members.4
METHODS AND ANALYSIS
Study design
This is a 5-year follow-up of a prospective observational
study of the ASPIRE-S cohort of patients with
stroke.2 4 11 The ASPIRE-S study recruited patients with
acute stroke in 2011–2012. A total of 256 patients and
their family members or carers were last followed up at
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6 months post-stroke. This cohort will be followed up
again, 5 years post-stroke (2016–2017), with a compre-
hensive assessment of clinical and cognitive measures. A
detailed health assessment will be conducted, including
cognitive function, adherence to secondary prevention
and cardiovascular risk factor control. Data will be col-
lected using a combination of clinical and laboratory
measurements using standard data collection forms,
interviewer and self-completion questionnaires.
Sample size
All participants from the original study will be eligible to
participate. On the basis of an estimated rate of attrition
of 30% (including death and other loss to follow-up), it
is anticipated that c. 180 patients and their family
members or carers will be reassessed.
Outcomes
Cardiovascular risk factor control
Secondary prevention will be assessed using a number of
clinical measures as part of a health assessment, includ-
ing height and weight, blood pressure, pulse, anticoagu-
lation, blood analysis and breath analysis (table 1).
Analysis of serum total cholesterol, calculated LDL chol-
esterol and blood glucose will be carried out on all parti-
cipants. Diabetic patients will also have glycated
haemoglobin assessed.
Secondary preventive medications
Reported medications at the time of follow-up will be
recorded as part of the interviewer-administered patient
questionnaire, and conﬁrmed with prescription reﬁll
data where possible.
Medication adherence
There is no consensus on the best measure to deﬁne
medication adherence.14 Combining prescription reﬁll
data with self-reported measures of adherence is consid-
ered essential to capturing the full extent to which
patients are (non-)adherent.15 Thus, adherence to
secondary preventive medications will be assessed using
a number of methods:
Prescription refills
Participants who are eligible for the General Medical
Services (GMS) scheme will be asked for permission to
access records of monthly dispensed medications from
the Irish Health Service Executive Primary Care
Reimbursement Service (HSE-PCRS) database. Access to
the GMS scheme, which provides free general practi-
tioner (GP) and hospital visits, and prescription medica-
tions at minimal cost, is means-tested for persons aged
<70 years, with a substantially higher income threshold
for the over 70 s,26 such that over 90% of those over 70
in Ireland are included in the scheme. As a result,
members of the scheme are representative of the Irish
population of over-70 s, but this is not the case for those
aged under 70, where women and those in lower socio-
economic groups are over-represented. The HSE-PCRS
pharmacy claims database provides details on monthly
dispensed medications for each individual in the
scheme.26 Prescription reﬁlls provide an objective esti-
mate of medication adherence, circumventing the
problem of incorrect self-reporting of medication adher-
ence.14 16 25 27 Prescription reﬁlls can be used to calcu-
late metrics such as the proportion of days covered—the
sum of the days supplied for medications within each
medication class, divided by the number of days in the
study period.14 15 This method has been adopted by
another recent study on adherence to secondary pre-
ventive medications post-stroke.21
Self-reported medication adherence
Self-reported medication adherence will be assessed
using the Medication Adherence Report Scale (MARS-5),28
a ﬁve-point scale that assesses both intentional and unin-
tentional non-adherence. The eight-item Morisky
Medication Adherence Scale (MMAS),29 which assesses
a number of medication-taking behaviours, will also be
included.
Pill counts
The research team will conduct pill counts of the
remaining tablets in each medication or blister pack, to
assess to what extent patients have taken medications as
prescribed. In addition to providing a more comprehen-
sive account of medication-taking, the use of several
methods to estimate adherence will allow exploration of
the levels of agreement between self-reported
Table 1 Clinical measures to be collected as part of a
health assessment
Clinical
measure Details
Blood pressure Three measurements will be taken with
the average of the last two readings
used for analysis. Twenty-four-hour BP
monitoring will also be performed
where possible.
Pulse Where the pulse is found to be
irregular, an ECG will be arranged to
confirm atrial fibrillation.
Anticoagulation Record of the last three INR
measurements to assess the safety of
anticoagulation medication, where
relevant
Blood analysis To assess serum total cholesterol, HDL
cholesterol and calculated LDL
cholesterol, glucose and HbA1c
Weight and
height
To assess BMI
Breath analysis Carbon monoxide monitoring to confirm
non-smoking status in former smokers
BMI, body mass index; BP, blood pressure; HbA1c, glycated
haemoglobin; HDL, high-density lipoprotein; INR, international
normalised ratio; LDL, low-density lipoprotein.
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medication adherence, pill counts and adherence esti-
mates using pharmacy prescription reﬁll data, which has
not previously been reported for patients with stroke.
Stroke recurrence and other cardiovascular events
In order to ascertain stroke recurrence or other cardio-
vascular events, participants will be asked if they have
experienced a stroke or other cardiovascular event since
the last assessment. Stroke and other cardiovascular
event occurrence will also be ascertained from partici-
pants’ hospital medical notes, based on recording of
diagnosis or other mention in the record.
Cognitive function
Cognitive function will be assessed using a number of
standardised, validated instruments, including the
Montreal Cognitive Assessment (MoCA),30 the National
Institute of Neurological Disorders and Stroke (NINDS)
30 min test battery,31 and the Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE)32 (table 2).
Rehabilitation and healthcare usage
A number of questions on use of physiotherapy, occupa-
tional therapy, psychology, and speech and language
therapy in the past 12 months, and the perceived need
for these services, will be included in the patient assess-
ment. Questions on healthcare usage, adapted from The
Irish Longitudinal Study on Ageing,44 will also be
included. These questions will assess use of GP and
nursing services, inpatient and outpatient hospital care,
use of mental health services, home help and home
care, and meals-on-wheels in the past 12 months. In add-
ition, the Timed Up and Go test, a performance-
orientated mobility assessment tool used to identify
individuals at increased risk of falls,33 and a number of
questions on falls adapted from the Irish Longitudinal
Study on Ageing, will be included.
Covariates
A range of demographic information, including age,
education, occupational status, marital status and living
arrangements, will be collected as part of the patient
and family member/carer assessments. The patient
assessment will also include questions relating to lifelong
learning, social participation and current smoking.
Potential barriers to medication adherence will be explored
using the Beliefs about Medicines Questionnaire (BMQ),28
which assesses concerns and perceived necessity of medica-
tions. Beliefs of patients with stroke about medicines have
been reported to be associated with non-adherence, with
non-adherent patients scoring lower on the positive beliefs
dimensions of the BMQ (necessity and beneﬁt) and higher
on negative beliefs (concern, overuse and harm).34
The Frenchay Aphasia Screening Test (FAST)35 will be
used to screen for communication problems that may
affect performance on cognitive assessments. Quality of
life and health and well-being status will be assessed
using the ICEpop CAPability measure for Older people
(ICECAP-O),36 the EQ-5D37 and the Stroke Speciﬁc
Quality of Life Scale (SSQOL).38 Finally, the
Nottingham Extended Activities of Daily Living Scale,39
which assesses activities that may be important to
patients with stroke who have been discharged home,
and the Vulnerable Elders Scale (VES),40 a simple
function-based tool for identifying older persons who
may be at risk of health deterioration, will be included.
Family member and carer assessments
In addition to the patient assessment, family members
or carers will be asked to complete a family member or
carer assessment. This assessment will involve a self-
completion questionnaire that includes the IQCODE32
and the Neuropsychiatric Inventory, Questionnaire
Version (NPI-Q) from the NINDS test battery, as well as
a number of questions regarding the extent to which
patients receive assistance with taking medications. The
use of informant report in addition to patient assess-
ments will facilitate triangulation of measures of cogni-
tion and increase the validity of the ﬁndings.
Furthermore, informant report is important in cases
where patients receive help from carers with medication
taking, as there is a lack of data on factors affecting
medication adherence in patients relying on others for
medication management.41
The family member and carer assessment will also
include a measure of anxiety (the Hospital Anxiety and
Depression Scale—Anxiety (HADS-A))42 and depression
(the Centre for Epidemiologic Studies Depression Scale
(CES-D)),43 and vulnerability (VES).40 These measures
Table 2 Cognitive assessments
Assessment Details
Patient
MoCA30 A rapid screening instrument for
global cognitive function, which has
exhibited good sensitivity and
specificity for mild cognitive
impairment
NINDS 30 mintest
protocol31
A 30 min neuropsychological
assessment battery that includes:
▸ Semantic fluency (Animal
Naming)
▸ Phonemic fluency (Controlled
Oral Word Association Test)
▸ Digit Symbol-Coding
▸ Verbal Learning Test
▸ Centre for Epidemiologic Studies
—Depression Scale NPI-Q
▸ Trail Making Test
Carer/family member
IQCODE32 An informant-reported assessment
of cognitive function
IQCODE, Informant Questionnaire on Cognitive Decline in the
Elderly; MoCA, Montreal Cognitive Assessment; NINDS, National
Institute of Neurological Disorders and Stroke; NPI-Q, Neuropsychiatric
Inventory, Questionnaire Version.
4 Rohde D, et al. BMJ Open 2017;7:e014819. doi:10.1136/bmjopen-2016-014819
Open Access
group.bmj.com on March 30, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
were included in the original ASPIRE-S study, which
reported substantial levels of anxious and depressive
symptoms among carers, linked to anxiety, depressive
symptoms and cognitive impairment in the patients with
stroke.4 By repeating the measures of emotional distress
and vulnerability included in the original ASPIRE-S
study, we will be able to consider carer well-being over
time, and explore the associations between changes in
cognitive impairment in patients with stroke and emo-
tional distress and vulnerability in carers or family
members.
Follow-up procedure
Each potential participant’s consultant physician will be
contacted to request permission to contact patients and
their GPs. Efforts will be made to identify deceased par-
ticipants prior to contact being made, using, for
example, hospital and GP records, as well as a widely
used website of death notiﬁcations (RIP.ie). Participants
will be sent a study information pack by post, containing
a cover letter, patient and family member/carer informa-
tion leaﬂets, and a stamped addressed postcard that can
be returned by participants wishing to opt out of the
study. The cover letter will advise patients and family
members that they will be contacted by phone by the
research team to discuss their participation in the study,
unless they return the postcard or inform their consult-
ant that they do not wish to be contacted.
Participants will then be contacted by phone to
discuss the study and to ascertain their interest in partici-
pating in the follow-up. If participants agree, a meeting
will be arranged with two members of the research
team, in the participants’ own home, at a hospital or
another location convenient to participants, and written
consent will be obtained. In cases where signiﬁcant cog-
nitive deﬁcits are suspected, either by the patient’s GP
or members of the research team conducting the
follow-up phone calls, contact will be made with the
patient’s family member or carer, who will be requested
to be present at the time of interview. The research
team will attempt to carry out individual interviews with
all patients. Assisted self-interviews, in which the partici-
pant can answer most of the questions but requires
some help from a family member or carer, may also be
used. This procedure has been used by follow-up waves
of the Irish Longitudinal Study on Ageing.44 If a partici-
pant is unable to complete an interview (cognitively or
physically), the family member or carer will still be eli-
gible to complete the family member/carer assessment.
Data analysis
Data will be analysed and reported using descriptive sta-
tistics, including means and SDs for normally distributed
data, medians and IQRs for non-normally distributed
data, and frequencies and percentages, as appropriate.
Adjusted associations between medication (non-)adher-
ence, (uncontrolled) cardiovascular risk factors and cog-
nitive function will be assessed using multivariate
regression models. The predicted sample size of 180 and
an estimated prevalence of cognitive impairment of 50%
will permit the inclusion of ∼9 variables in multivariate
analyses.45 Covariates that are associated with each
outcome at the p<0.10 level will be included in multi-
variate models. Agreement between measures of medica-
tion adherence will be assessed using the κ statistic.26
ETHICS AND DISSEMINATION
Treatment of study participants
Participants will continue to receive standard care
throughout the study period from their hospital consult-
ant or GP. If participants become distressed or otherwise
unwell during the interview or health assessment, the
interview or assessment will be terminated immediately,
and the interviewer will call back within 24 hours to see
how the participant is. The family member/carer and
GP or consultant will be informed that the patient
became upset during the course of the interview and, if
appropriate, that the patient would like to talk to a
member of the medical team. Although potential harm
is expected to be minimal, some participants may experi-
ence temporary and localised discomfort, mild pain or
bruising as a result of venepuncture or blood pressure
assessment.
Dissemination
Findings from this study will be disseminated through
presentations in academic fora and to relevant policy-
maker, practitioner and stakeholder audiences, and
through peer-reviewed publications.
LIMITATIONS
This study has a number of limitations, including the reli-
ance on self-report or carer report to ascertain usage of
healthcare services. Unfortunately, owing to the complex
system of public/private healthcare provision in Ireland,
and the lack of universal patient identiﬁers, there is cur-
rently no alternative method available to collect this infor-
mation. While every effort will be made to follow-up all
patients still alive from the original study, patients with
more severe cognitive decline may be more likely to be
lost to follow-up, which could lead to an underestimation
of the prevalence of cognitive impairment in this cohort.
Since this is a follow-up study, the sample size will be
based on the availability of participants, rather than a stat-
istical power calculation. It is possible that the analyses for
some associations of interest will be underpowered. While
we will aim to assess and adjust for a number of known
confounders, owing to the observational nature of this
study, there may be other unknown or unmeasured con-
founding factors. However, given the fact that longer
term follow-up studies of patients with stroke are relatively
rare, and no such studies exist in Ireland, recalling this
cohort provides a unique opportunity to explore longer
term secondary prevention and cognitive function in
patients with stroke.
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CONCLUSION
Given the potential public health burden of cognitive
impairment after stroke, identiﬁcation of modiﬁable risk
and protective factors to avert or delay cognitive decline
is paramount. Delaying cognitive impairment could
allow many individuals to reach the end of their natural
lifespan before crossing the threshold for dementia.46
While effective vascular risk factor management through
secondary prevention may reduce the burden of post-
stroke cognitive impairment,2 7 8 there is a lack of data
on longer term treatment continuation and adherence
rates in patients with stroke. Similarly, there are currently
no Irish data on the costs of cognitive impairment or
inadequate secondary prevention post-stoke. This study
will provide valuable information on the trajectories of
cognitive impairment, medication adherence and car-
diovascular risk factors post-stroke, and will indicate how
cognitive function and secondary prevention are related
to each other, as well as to stroke or other cardiovascular
event recurrence and healthcare usage, over time. These
ﬁndings can help inform future health policy and
service planning regarding the longer term manage-
ment of patients with stroke.
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